Skip to main content
Premium Trial:

Request an Annual Quote

PGXL, Silicon Biosystems Partner on DEPArray Technology

NEW YORK (GenomeWeb News) – PGXL Technologies and Silicon Biosystems today announced a deal to make Silicon Bio's DEPArray technology available through PGXL.

As a result of the partnership, clinical researchers and pharmaceutical sponsors will be able to "obtain the level of data fidelity and resolution needed in cancer biomarker discovery and translational research," the two companies said.

The DEPArray technology is based on dielectrophoresis for isolating and manipulating cells in a suspension matrix. Silicon Bio said that it can be used to investigate the underlying causes of disease, disease progression, and the basis of drug resistance and efficacy.

Bob Proulx, president and general manager of Silicon Bio's US operations, said that there has been gathering interest in having DEPArray available on a fee-for-service basis. The company last year added a demonstration and training laboratory, "but partnering with PGXL for [contract research organization] services will add a whole new dimension to our ability to reach and impact the market … We partnered with PGXL because they bring highly complementary capabilities and expertise to the equation," he said.

The DEPArray technology and supporting technologies will be available in the summer.

Financial and other terms of the deal were not disclosed.